Table 3.

Therapeutic Targeting of Cytokine Signaling Pathways in Immune-Mediated Sensorineural Hearing Loss

Drug Class	Therapeutic Agent	Publication
Corticosteroids	Prednisone/Methylprednisolone	Shamriz et al. (2018)
		You et al. (2020)
		Liu et al. (2019)
		Das et al (2019)
		Penêda et al. (2019)
		Zou et al. (2019)
		Carre et al. (2020)
		Oz et al. (2019)
		Padoan et al. (2019)
		Tripathi et al. (2018)
		Perez-Carpena et al. (2020)
		Mancini et al. (2018)
		D’Aguanno et al. (2018)
		Lu et al. (2019)
IL-1 Inhibitors	Anakinra	Penêda et al. (2019)
		Kim et al. (2021)
		Hui et al. (2019)
		Mancini et al. (2018)
		Kareva et al. (2020)
		Welzel et al. (2021)
		Iida et al. (2019)
		Williams et al. (2019)
	Canakinumab	Hui et al. (2019)
		Kareva et al. (2020)
		Welzel et al. (2021)
		Iida et al. (2019)
		Williams et al. (2019)
	Rilonacept	Kareva et al. (2020)
		Welzel et al. (2021)
		Iida et al. (2019)
		Williams et al. (2019)
IL-6 Inhibitors	Tocilizumab	Yan et al. (2020)
		Espinoza et al. (2020)
TNF-α Inhibitors	Infliximab	Espinoza et al. (2020)
		Das et al (2019)
		Shamriz et al. (2018)
		Sakano et al. (2019)
		Padoan et al. (2019)
		Mata-Castro et al. (2020)
		Mancini et al. (2018)
	Etanercept	Shamriz et al. (2018)
		Orlando et al. (2021)
	Golimumab	Sakano et al. (2019)
		Mancini et al. (2018)
	Adalimumab	Shamriz et al. (2018)
		Liu et al. (2019)
		Utsunomiya et al. (2019)
		Mancini et al. (2018)
B-cell Inhibitors	Rituximab	Shamriz et al. (2018)
		Liu et al. (2019)
		Das et al (2019)
		Espinoza et al. (2020)
		San et al. (2019)
		Monferrer-Adsuara et al. (2020)
JAK Inhibitors	Tofacitinib	Jamilloux et al. (2019)